drugset / Trial / NCT00958581

Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

NCT00958581

Phase 4 Completed 177 enrolled NYU Langone Health
RandomizedParallel-groupTriple-blindTreatment

Summary

Tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) have been reported to reduce blood loss in the cardiac surgery literature but they have not been reported in use head-to-head in the orthopedic surgery literature. In a randomized, double-blind, prospective study we believe that TXA will be more effective than both EACA and placebo at reducing blood loss for corrective spinal surgery.

Timeline

Start
2008-12
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminocaproic Acid Small molecule 10 mg/kg
Subject Tranexamic Acid Small molecule 1 mg/kg

Indications